Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer

Sameer A. Siddiqui, Shomik Sengupta, Jeffrey M. Slezak, Eric J. Bergstralh, Bradley C. Leibovich, Robert P. Myers, Horst Zincke, Michael L. Blute

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Purpose: Historically young patients with prostate cancer have been found to have poorer outcomes. Recent studies suggest favorable pathological findings and improved survival in younger patients undergoing RRP. We assessed age at treatment as a predictor of post-RRP survival. Materials and Methods: We identified 5,509 patients treated with RRP for prostate cancer at our institution between 1987 and 1995. Age at treatment was classified into categories of younger than 55, 55 to 59, 60 to 64, 65 to 69 and 70 years or older. CSS, sPFS and biochemical PFS were estimated by the Kaplan-Meier method and analyzed using Cox proportional hazard models. Results: Younger patients had lower preoperative prostate specific antigen, and tumor grade and stage. CSS, sPFS and biochemical PFS were similar across age groups but overall survival decreased with older age at treatment. After multivariate adjustment the risk of cancer death was lower in patients 70 years or older (RR 0.53, 95% CI 0.30 to 0.90), while the risk of progression was lower in all age groups compared to that in men younger than 55 years (RR 0.57 to 0.62). On stratified subset analysis sPFS was progressively worse with younger age in patients with high risk pathological findings. However, the addition of age to multivariate models incorporating preoperative prostate specific antigen, pathological features and adjuvant therapy failed to improve their predictive value for CSS and sPFS. Conclusions: Despite more favorable clinicopathological features younger patients undergoing RRP for prostate cancer have survival similar to that of older counterparts. Given the greater proportionate impact of prostate cancer on survival, it is particularly important to pursue aggressive treatment in younger patients.

Original languageEnglish (US)
Pages (from-to)952-957
Number of pages6
JournalJournal of Urology
Volume175
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Prostatectomy
Prostatic Neoplasms
Survival
Prostate-Specific Antigen
Age Groups
Risk Adjustment
Therapeutics
Proportional Hazards Models
Neoplasms

Keywords

  • Age groups
  • Mortality
  • Prostate
  • Prostatectomy
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Siddiqui, S. A., Sengupta, S., Slezak, J. M., Bergstralh, E. J., Leibovich, B. C., Myers, R. P., ... Blute, M. L. (2006). Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. Journal of Urology, 175(3), 952-957. https://doi.org/10.1016/S0022-5347(05)00339-3

Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. / Siddiqui, Sameer A.; Sengupta, Shomik; Slezak, Jeffrey M.; Bergstralh, Eric J.; Leibovich, Bradley C.; Myers, Robert P.; Zincke, Horst; Blute, Michael L.

In: Journal of Urology, Vol. 175, No. 3, 03.2006, p. 952-957.

Research output: Contribution to journalArticle

Siddiqui, SA, Sengupta, S, Slezak, JM, Bergstralh, EJ, Leibovich, BC, Myers, RP, Zincke, H & Blute, ML 2006, 'Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer', Journal of Urology, vol. 175, no. 3, pp. 952-957. https://doi.org/10.1016/S0022-5347(05)00339-3
Siddiqui, Sameer A. ; Sengupta, Shomik ; Slezak, Jeffrey M. ; Bergstralh, Eric J. ; Leibovich, Bradley C. ; Myers, Robert P. ; Zincke, Horst ; Blute, Michael L. / Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. In: Journal of Urology. 2006 ; Vol. 175, No. 3. pp. 952-957.
@article{a095df46102142e3b4a27cc471157b17,
title = "Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer",
abstract = "Purpose: Historically young patients with prostate cancer have been found to have poorer outcomes. Recent studies suggest favorable pathological findings and improved survival in younger patients undergoing RRP. We assessed age at treatment as a predictor of post-RRP survival. Materials and Methods: We identified 5,509 patients treated with RRP for prostate cancer at our institution between 1987 and 1995. Age at treatment was classified into categories of younger than 55, 55 to 59, 60 to 64, 65 to 69 and 70 years or older. CSS, sPFS and biochemical PFS were estimated by the Kaplan-Meier method and analyzed using Cox proportional hazard models. Results: Younger patients had lower preoperative prostate specific antigen, and tumor grade and stage. CSS, sPFS and biochemical PFS were similar across age groups but overall survival decreased with older age at treatment. After multivariate adjustment the risk of cancer death was lower in patients 70 years or older (RR 0.53, 95{\%} CI 0.30 to 0.90), while the risk of progression was lower in all age groups compared to that in men younger than 55 years (RR 0.57 to 0.62). On stratified subset analysis sPFS was progressively worse with younger age in patients with high risk pathological findings. However, the addition of age to multivariate models incorporating preoperative prostate specific antigen, pathological features and adjuvant therapy failed to improve their predictive value for CSS and sPFS. Conclusions: Despite more favorable clinicopathological features younger patients undergoing RRP for prostate cancer have survival similar to that of older counterparts. Given the greater proportionate impact of prostate cancer on survival, it is particularly important to pursue aggressive treatment in younger patients.",
keywords = "Age groups, Mortality, Prostate, Prostatectomy, Prostatic neoplasms",
author = "Siddiqui, {Sameer A.} and Shomik Sengupta and Slezak, {Jeffrey M.} and Bergstralh, {Eric J.} and Leibovich, {Bradley C.} and Myers, {Robert P.} and Horst Zincke and Blute, {Michael L.}",
year = "2006",
month = "3",
doi = "10.1016/S0022-5347(05)00339-3",
language = "English (US)",
volume = "175",
pages = "952--957",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer

AU - Siddiqui, Sameer A.

AU - Sengupta, Shomik

AU - Slezak, Jeffrey M.

AU - Bergstralh, Eric J.

AU - Leibovich, Bradley C.

AU - Myers, Robert P.

AU - Zincke, Horst

AU - Blute, Michael L.

PY - 2006/3

Y1 - 2006/3

N2 - Purpose: Historically young patients with prostate cancer have been found to have poorer outcomes. Recent studies suggest favorable pathological findings and improved survival in younger patients undergoing RRP. We assessed age at treatment as a predictor of post-RRP survival. Materials and Methods: We identified 5,509 patients treated with RRP for prostate cancer at our institution between 1987 and 1995. Age at treatment was classified into categories of younger than 55, 55 to 59, 60 to 64, 65 to 69 and 70 years or older. CSS, sPFS and biochemical PFS were estimated by the Kaplan-Meier method and analyzed using Cox proportional hazard models. Results: Younger patients had lower preoperative prostate specific antigen, and tumor grade and stage. CSS, sPFS and biochemical PFS were similar across age groups but overall survival decreased with older age at treatment. After multivariate adjustment the risk of cancer death was lower in patients 70 years or older (RR 0.53, 95% CI 0.30 to 0.90), while the risk of progression was lower in all age groups compared to that in men younger than 55 years (RR 0.57 to 0.62). On stratified subset analysis sPFS was progressively worse with younger age in patients with high risk pathological findings. However, the addition of age to multivariate models incorporating preoperative prostate specific antigen, pathological features and adjuvant therapy failed to improve their predictive value for CSS and sPFS. Conclusions: Despite more favorable clinicopathological features younger patients undergoing RRP for prostate cancer have survival similar to that of older counterparts. Given the greater proportionate impact of prostate cancer on survival, it is particularly important to pursue aggressive treatment in younger patients.

AB - Purpose: Historically young patients with prostate cancer have been found to have poorer outcomes. Recent studies suggest favorable pathological findings and improved survival in younger patients undergoing RRP. We assessed age at treatment as a predictor of post-RRP survival. Materials and Methods: We identified 5,509 patients treated with RRP for prostate cancer at our institution between 1987 and 1995. Age at treatment was classified into categories of younger than 55, 55 to 59, 60 to 64, 65 to 69 and 70 years or older. CSS, sPFS and biochemical PFS were estimated by the Kaplan-Meier method and analyzed using Cox proportional hazard models. Results: Younger patients had lower preoperative prostate specific antigen, and tumor grade and stage. CSS, sPFS and biochemical PFS were similar across age groups but overall survival decreased with older age at treatment. After multivariate adjustment the risk of cancer death was lower in patients 70 years or older (RR 0.53, 95% CI 0.30 to 0.90), while the risk of progression was lower in all age groups compared to that in men younger than 55 years (RR 0.57 to 0.62). On stratified subset analysis sPFS was progressively worse with younger age in patients with high risk pathological findings. However, the addition of age to multivariate models incorporating preoperative prostate specific antigen, pathological features and adjuvant therapy failed to improve their predictive value for CSS and sPFS. Conclusions: Despite more favorable clinicopathological features younger patients undergoing RRP for prostate cancer have survival similar to that of older counterparts. Given the greater proportionate impact of prostate cancer on survival, it is particularly important to pursue aggressive treatment in younger patients.

KW - Age groups

KW - Mortality

KW - Prostate

KW - Prostatectomy

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=32044460619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044460619&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(05)00339-3

DO - 10.1016/S0022-5347(05)00339-3

M3 - Article

C2 - 16469591

AN - SCOPUS:32044460619

VL - 175

SP - 952

EP - 957

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -